Quarterly report [Sections 13 or 15(d)]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Reconciles Segment Direct Profit or Loss

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

Three Months Ended March 31,

 

(in thousands)

2025

 

 

2024

 

Research and development:

 

 

 

 

 

QTORIN rapamycin for microcystic LM

$

1,154

 

 

$

3

 

QTORIN rapamycin for microcystic LM - Government grant income

 

(127

)

 

 

 

QTORIN rapamycin for cutaneous VM

 

321

 

 

 

 

QTORIN rapamycin CMC

 

785

 

 

 

113

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

Salaries and stock-based compensation

 

1,322

 

 

 

647

 

Consultants

 

247

 

 

 

173

 

Other

 

372

 

 

 

48

 

Total research and development

$

4,074

 

 

$

984

 

General and administrative:

 

 

 

 

 

Salaries and stock-based compensation

$

1,453

 

 

$

346

 

Consultants

 

1,062

 

 

 

223

 

Other

 

1,282

 

 

 

206

 

Total general and administrative

$

3,797

 

 

$

775

 

Loss from operations

$

(7,871

)

 

$

(1,759

)